after joining the study, you will sign a consent form that explains the purpose of the long‑term follow‑up and what will be required of you.

the research team will confirm that you have completed the previous au‑011‑301 trial and meet the eligibility criteria for the follow‑up.

a comprehensive eye examination will be performed, including imaging of the choroidal melanoma and measurement of visual acuity using the etdrs chart.

the results will serve as the reference point for all future comparisons.

the study medication, bel‑sar (belzupacap sarotalocan), was given as a single ocular injection of 80 µg in a solution for injection during the original trial.

no additional doses are scheduled during the long‑term follow‑up, but the previous dose will be considered when evaluating safety and effectiveness.

you will attend scheduled visits, typically every six months, for up to several years.

each visit includes an eye exam, imaging to assess tumor size and thickness, and a visual acuity test to detect any loss of vision.

the team will record any new symptoms, side effects, or changes in health.

any occurrence of adverse events (unwanted medical problems) or signs of tumor progression will be documented.

the study will track the time until tumor growth, vision loss of 15 letters or more, and any need for additional eye treatments.

information collected will help determine the long‑term safety and efficacy of bel‑sar.